title: Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
abstract: The aim of this study was to develop a spray dried submicrometer powder formulation suitable for the excipient enhanced growth (EEG) application. Combination particles were prepared using the Buchi Nano spray dryer B-90. A number of spray drying and formulation variables were investigated with the aims of producing dry powder formulations that were readily dispersed upon aerosolization and maximizing the fraction of submicrometer particles. Albuterol sulfate, mannitol, L-leucine, and poloxamer 188 were selected as a model drug, hygroscopic excipient, dispersibility enhancer and surfactant, respectively. Formulations were assessed by scanning electron microscopy and aerosol performance following aerosolization using an Aerolizer dry powder inhaler (DPI). In vitro drug deposition was studied using a realistic mouth-throat (MT) model. Based on the in vitro aerosolization results, the best performing submicrometer powder formulation consisted of albuterol sulfate, mannitol, L-leucine and poloxamer 188 in a ratio of 30:48:20:2, containing 0.5% solids in a water:ethanol (80:20%, v/v) solution which was spray dried at 70 °C. The submicrometer particle fraction (FPF(1 μm/ED)) of this final formulation was 28.3% with more than 80% of the capsule contents being emitted during aerosolization. This formulation also showed 4.1% MT deposition. The developed combination formulation delivered a powder aerosol developed for the EEG application with high dispersion efficiency and low MT deposition from a convenient DPI device platform.
authors: Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA. yeonju.sohn@gmail.com
authors: Yoen-Ju
authors: YJ
authors: Son
authors: P
authors: P
authors: Worth Longest
authors: Michael
authors: M
authors: Hindle
mesh_terms: D000280:Administration, Inhalation; D000336:Aerosols; D000420:Albuterol / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D002152:Calorimetry, Differential Scanning; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid; D058995:Dry Powder Inhalers; D004867:Equipment Design; D005079:Excipients / Q000737:chemistry*; D006801:Humans; D008855:Microscopy, Electron, Scanning; D008953:Models, Anatomic; D009055:Mouth / Q000378:metabolism; D010316:Particle Size; D010614:Pharynx / Q000378:metabolism; D011208:Powders; D013499:Surface Properties; D014018:Tissue Distribution
chemical_list: D000336:Aerosols; D001993:Bronchodilator Agents; D005079:Excipients; D011208:Powders; D000420:Albuterol